

**PE/iFluor™ 750 Anti-human CD7 Antibody**  
**\*HIT7\***Catalog number: 100701R0, 100701R1, 100701R2  
Unit size: 25 tests, 100 tests, 500 tests**Product Details**

Storage Conditions	2-8°C with minimized light exposure. Do not freeze.
Expiration Date	12 months upon receiving
Concentration	0.1 mg/mL
Formulation	Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

**Antibody Properties**

Species Reactivity	Human
Class	Primary
Clonality	Monoclonal
Host	Mouse
Isotype	Mouse IgG1
Immunogen	CD7 (gp40, TP41)
Clone	HIT7
Conjugate	PE/iFluor™ 750

**Biological Properties**

Preparation	Antibody purified by affinity chromatography and then conjugated with PE/iFluor™ 750 under optimal conditions
Application	Flow Cytometry (FACS)

**Spectral Properties**

Conjugate	PE/iFluor™ 750
Excitation Wavelength	566 nm
Emission Wavelength	778 nm

**Applications**

HIT7 is an anti-human monoclonal antibody that recognizes the CD7 antigen. CD7 (also known as gp40) is a 40 kD single-pass type I membrane protein that is located on the surface of cells like NK cells, stem cells and T cells. CD7 has been closely linked to essential biological processes such as immune response, particularly adaptive immune response. Furthermore, it is involved with important cellular pathways, namely, the transmembrane receptor protein tyrosine kinase signaling pathway. From a research standpoint, it is of biological interest due to its association with vital macromolecules/ligands like PI3-Kinase. CD7 is a fairly uncommon antibody target, with a little more than 3600 publications in the last

decade. Even still, CD7 is commonly used in flow cytometry applications as a phenotypic marker for differentiation of cell types, especially in the study of immunology and costimulatory molecules. This antibody was purified through affinity chromatography and conjugated to PE/iFluor™ 750 (ex/em = 566/778 nm). It is compatible with the 561 nm laser and 780/60 nm bandpass filter (for example, as in the Agilent Technologies NovoCyte).